Biotop-report 2011

9

B i o T O P i c s   4 2 _

B i o T O P   R e p o r t   2 0 1 1

World Health Summit

Under the patronage of German Federal Chancellor Angela Merkel 

and French President Nicolas Sarkozy Charité - Universitätsmed-

izin Berlin organised the World Health Summit in cooperation 

with the M8 Alliance of Academic Health Centres and Medical Uni-

versities. For the second time this summit of leading representa-

tives from medicine, science, politics, business and civil society 

convened to discuss the major challenges in medical research 

and healthcare and develop strategic solutions. The World Health 

Summit published results and recommendations which are made 

available to deciders in politics, science, research and the health-

care systems. It provided a unique opportunity to meet leading 

international personalities who are shaping medicine, research, 

health policy and global health strategies around the world. The 

objective in the many different discussions at the summit was to 

develop convincing and up-to-date core messages for the devel-

opment of the innovation capacity of medicine and for tackling 

key global health challenges. 

For 2011, the World Health Summit under the motto “Today’s 

Science – Tomorrow’s Agenda”, will focus on non-communicable 

diseases and the role of mass media in health promotion, new 

approaches in research and innovation, ensuring public health in 

times of climate change and innovative models in global health 

governance.

Prof. Dr. Vera Regitz-Zagrosek

Director of the Institute of Gender in Medicine (GiM) 

Charité – Universitätsmedizin Berlin

Cardiovascular Research Expands

»

Berlin plays a key role in the newly founded German 

Centre for Cardiovascular Research (DZHK). The Chari-

té, the German Heart Institute Berlin (DHZB) and the Max 

Delbrück Centre for Molecular Medicine will combine their 

cardiovascular and metabolism research under the name 

“Cardio Berlin” within the DZHK. Cardio Berlin is focusing 

on prevention and also plans to research gender differences 

between men and women in cardiovascular diseases. Clini-

cal experts and researchers in a wide range of disciplines 

are working together here and applying state-of-the-art 

molecular genetics methods and imaging processes as well 

as holistic approaches (systems biology).

Financing and Added Value

VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank 

Berlin (IBB) and the State of Berlin. It is co-fi nanced by the European Regional De-

velopment Fund (ERDF). 

VC Fonds Technologie 

Berlin

Venture Capital 

for companies in Berlin

IBB Beteiligungsgesellschaft mbH offers equity fi nanc-

ing for high tech companies in Berlin. For our fund 

VC Fonds 

Technologie

 Berlin

 (€52m) we are looking 

for investment opportunities in the biotechnology and 

medical technology sector. 

Our investment approach is based on hands-on 

invol 

vement and active management support for 

each portfolio company, delivered by our highly expe-

rienced investment team. 

VC Fonds 

Technologie

 Berlin

not only provides capital, but also helps execute the 

business plan. 

Are you interested? Please do not hesitate to contact us.

IBB Beteiligungsgesellschaft mbH

Mrs. Ute Mercker / Mr. Christian Seegers

Bundesallee 171

10715 Berlin / Germany

Phone:  [phone]

www.ibb-bet.de

Selected portfolio companies:

---

10

B i o T O P i c s   4 2 _

B i o T O P   R e p o r t   2 0 1 1

Bioline

Bioline is a primary manufacturer and 

developer of a wide range of molecu-

lar biology products. Our manufacturing 

sites  are  ISO  9001:2008  certified  and 

strive to continuously improve the excel-

lence of operational routines and qual-

ity assurance system. All stages of the 

manufacturing process are controlled 

and monitored by stringent quality con-

trol procedures to guarantee the highest 

quality and lot-to-lot reproducibility.

We strive to maintain close contact with 

our customers, key partners and collab-

orators to keep us at the forefront of new 

application areas and technologies pro-

viding feedback to our R&D groups and 

leading to new sustainable solutions for 

the bio-research reagents market.

 

When your requirements are beyond the 

scope of our standard product range we 

invite you to take advantage of our bulk, 

custom and OEM service. 

For the last 19 years we have been pro-

viding custom made solutions to indus-

trial and bulk partners and welcome 

new  partners  with  specific  product 

needs.

Our products

 

p

Real-Time PCR Kits for standard 

and FAST cycling conditions

 

p

DNA Polymerases and Mixes

 

p

Reverse Transcription

 

p

Cloning Reagents

 

p

Nucleic Acid Isolation Kits

 

p

Ultra-Pure Nucleotides

 

p

DNA MW Markers

 

p

Competent Cells

 

p

Essential Reagents for molecular 

biology

Address

Bioline GmbH

Im Technologiepark TGZ II

14943 Luckenwalde

Contact

Holger Berthel

Sales Manager Germany

Phone [phone]

Fax 

[phone]

www.bioline.com

[e-mail]

Biochrom AG

Biochrom AG is a company dedicated to 

be a primary supplier of cell culture 

media and quality animal sera. 

The company manufactures and distrib-

utes the full range of products related to 

mammalian cell culturing technique: 

standard cell culture media, complete 

media tailored for particular cell types 

and cell lines, custom formulations, and 

animal sera, such as Fetal Bovine Serum 

(FBS). All sera are prescreened prior to 

acceptance; only those lots that meet 

strict quality control requirements are 

accepted for further processing and 

subsequent sale to customers. Serum 

products are tested for sterility, adventi-

tious viral agents, physico-chemical 

parameters, and biological performance. 

The manufacturing processes are 

de signed  for  the  specific  needs  of  cus-

tomers engaged in biotechnological 

research, development, and biophar-

maceutical production. Biochrom AG 

specializes in meeting customers‘ speci-

fications  and  regulatory  concerns,  to 

facilitate the manufacture of custom 

media consistent with Good Manufac-

turing Practice (GMP). The media are 

produced in a strictly controlled envi-

ronment; chemicals used conform, 

where applicable, to grade standards of 

European Pharmacopoeia and US 

Pharma copoeia. Biochrom AG produces 

lot sizes of sterile industrial buffers up 

to 4,000 litres, sterile media up to 2,000 

litres, powder media up to 20,000 litres 

and customized sizes in smallest quan-

tities. 

Biochrom AG and TPP Techno Plastic 

Products AG (Switzerland) are exclusive 

partners for the sale of TPP products for 

cell culture and general laboratory 

equipment in Germany.

Address

Biochrom AG

Leonorenstraße 2-6

12247 Berlin · Germany

Phone [phone]

Fax 

[phone]

[e-mail]

www.biochrom.de

---